AW
CLDX icon

Avion Wealth’s Celldex Therapeutics CLDX Stock Holding History

Avion Wealth’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-24
Closed – – 1458
2026
Q2 		$0 Hold
24
– – ﹤0.01% 1474
2026
Q1 		$0 Hold
24
– – ﹤0.01% 1289
2025
Q4 		$0 Hold
24
– – ﹤0.01% 1284
2025
Q3 		$0 Hold
24
– – ﹤0.01% 1251
2025
Q2 		$0 Buy
+24
New +$467 ﹤0.01% 1235

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
TSP Capital Management Group
TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return

Avion Wealth's CLDX Position: Q3 2026 in Review

Avion Wealth sold out of Celldex Therapeutics (CLDX) in Q3 2026, closing a stake of 24 shares.

Avion Wealth first reported a position in CLDX in Q2 2025 and held it in 5 quarters. The position peaked at $0 in Q2 2026. 108 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Avion Wealth reported no remaining Celldex Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Avion Wealth sold 24 Celldex Therapeutics shares in Q3 2026.
  • Avion Wealth first reported a position in Celldex Therapeutics in Q2 2025 and held it in 5 quarters.
  • Avion Wealth's Celldex Therapeutics position peaked at $0 in Q2 2026.
  • 108 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Avion Wealth's 13F filing for Q3 2026, filed 4 Nov 2026.